The invention is directed to biomedical polyurethanes. The invention is particularly directed to biomedical polyurethanes with improved biodegradability and to an improved preparation of the biomedical polyurethanes. In particular the present invention provides a biomedical polyurethane having the formula (A-B-C-B).sub.n, wherein A denotes a polyol, B denotes a diisocyanate moiety, C denotes a diol component and n denotes the number of recurring units, and wherein the B-C-B segment is bioresorbable.

A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided.

A method for forming a prosthesis comprising a bone-like portion and a cartilage-like portion can comprise additively manufacturing a first positive mold in accordance with a portion of a first three-dimensional model of a portion of a bone. A first negative mold can be formed from the first positive mold. The bone-like portion can be created within the first negative mold. A second positive mold of the bone and a cartilage can be additively manufactured from a second three-dimensional model. A portion of the second three-dimensional model can correspond to a portion of the first three-dimensional model. A second negative mold can be formed from the second positive mold. The bone-like portion can be positioned in the second negative mold so that the second negative mold and the bone-like portion can define a cartilage space that can be filled with a material to form the cartilage-like portion of the prosthesis.

The present invention provides a cell culture having a cartilage-like tissue forming property, including a cell population in which the expression intensity of at least one cell surface marker selected from the group consisting of CD166, CD165, CD99, GD2, STRO-1, CD108, CD164, CD6, CD106, and CD107b is not higher than the threshold for each cell surface marker, and/or, the expression intensity of at least one cell surface marker selected from the group consisting of CD26, CD73, CD105, CD44, CD120a, CD201, EGFR, CD146, CD140a, and CD90 is not lower than the threshold for each cell surface marker.

Described herein are regenerative approaches with tunable cell-cell and cell-matrix interactions to enhance the ability to regenerate multiple zones within a construct with each zone possessing a unique, optimum, level of cell-cell and cell-matrix interaction.

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

A device for endovascular treatment to ameliorate aneurysm recurrences by deploying a treatment mesh having a plurality of vertically oriented elongated support reinforcement elements that are substantially parallel and oriented upon a plane in communication with the mesh. Upon deployment, the array of distal ends of the support extensions and reinforcements are substantially oriented upon a plane, which plane is in substantially the same orientation as the opening of the aneurysm into which the device was deployed. The treatment mesh may incorporate a coating of hydrogel, optionally impregnated with pharmaceutical compounds.

A system for harvesting bone material from a bone may include a rotary cutter defining a rotary cutter longitudinal axis extending between a rotary cutter proximal end and a rotary cutter distal end. The rotary cutter may have a drive shaft configured to receive input torque, and an osteochondral cutter configured to cut the tissue and receive the tissue material in response to rotation of the osteochondral cutter under pressure against the tissue. The system may further include a bone port defining a bone port longitudinal axis extending between a bone port proximal end and a bone port distal end. The bone port may have a bone port cannulation sized to closely fit over the osteochondral cutter. At least one of the bone port proximal end and the bone port distal end may be securable to the tissue. A stratiform tissue graft may be delivered through the bone port.

The present invention relates to an in vitro method for creating a viable connective tissue and/or osseous tissue obtained by tribological solicitations of a biological culture. It further relates to a viable connective tissue and/or osseous tissue susceptible to be obtained by said method as well as to the use of said method or viable connective tissue and/or osseous tissue to prepare a biological implant.

Systems, methods, and kits are described for repairing a fibrocartilage defect in a subject. The fibrocartilage defect is contacted with a first composition containing an oxidized and methacrylated glycosaminoglycan to form an imine bond between the glycosaminoglycan and the fibrocartilage defect, thereby coating the fibrocartilage defect with the glycosaminoglycan. The fibrocartilage defect coated with the glycosaminoglycan is then contacted with a mixture of a pre-polymer hydrogel composition containing a first crosslinking unit that, when polymerized, is capable of bonding to methacrylate and a hydrogel polymerization initiator composition, thereby forming a hydrogel that is covalently bonded to the glycosaminoglycan through methacrylate.